Hematology Faculty
Division Chief
Ann Mullally, MD
Professor
Physician-scientist studying myeloid malignancies.
Major interests are myeloproliferative neoplasms (MPN) and clonal hematopoiesis (CH) .
Active areas of research include (i) biology & therapy of mutant calreticulin, (ii) JAK2V617F biology, (iii) clonal expansion of MPN stem cells, (iv) immunological approaches to target MPN.
Professors
Steven E. Artandi, MD, PhD
Jerome and Daisy Low Gilbert Professor,
Director of Stanford Cancer Institute
Understanding the early stages of cancer development
Mechanisms in dyskeratosis congenita and other degenerative diseases
Telomerase function inside human stem cells and cancer cells
Caroline Bérubé, MD
Clinical Associate Professor
Medical Director Outpatient Anticoagulation Clinic
General hematology
Specific interest in clinical thrombosis and hemostasis, management of anticoagulation, hemophilia, pregnancy-related hematologic conditions, immune thrombocytopenia, and anemia.
Ami Bhatt, MD, PhD
Professor
My laboratory uses molecular, micro- and computational biology techniques to dissect the role of the microbiota in hematological disorders.
We hope to target vulnerabilities in hematological disorders characterizing and modifying the human microbiota, thereby improving patient outcomes.
Roni Brar, MD
Clinical Assistant Professor
Optimizing clinical evaluation for patients with benign and malignant hematologic conditions.
Novel clinical trials for acute myeloid leukemia, chronic lymphocytic leukemia, multiple myeloma, and other hematologic malignancies.
Implementing personalized genomic medicine with high impact results into the clinic.
May Chien, MD
Clinical Assistant Professor
Gene therapy for hemophilia and understanding the pathophysiology of immune thrombocytopenia.
Tamara Dunn, MD
Clinical Assistant Professor
Program Director, Hematology Fellowship Program
Associate Chair of Diversity and Inclusion in the Department of Medicine
Bita Fakhri, MD, MPH
Assistant Professor
My research focus is on the development of novel therapies for chronic lymphocytic leukemia/small lymphocytic lymphoma, with a particular interest in cell-based therapies (bispecific T cell engagers), and new targets/pathways (BTK degraders and ROR1). My other area of focus is understanding the predictive and prognostic value of pathogenic mutations commonly seen in CLL/SLL and their association with clinical behavior. Last but not least, I have a genuine interest in clinical trial equity, and identifying the surmountable barriers to clinical trial enrollment among underserved and marginalized populations.
Lawrence Tim Goodnough, MD
Professor, Pathology & Medicine
Oversees and supervises rotation of Hematology/ Oncology fellows in Transfusion Service
Director, Transfusion Medicine Fellowship Program
Associate Medical Director, Stanford Blood Center
Jason R. Gotlib, MD
Professor
Phase I/II trial evaluation of novel therapies for myelodysplastic syndromes, acute myelogenous leukemia, chronic myelogenous leukemia, and chronic myeloproliferative disorders (MPDs, eg. polycythemia vera, essential thrombocythemia, primary myelofibrosis, hypereosinophilic syndromes, and systemic mastocytosis) Translational research collaborations to interrogate the molecular basis of CML and chronic MPDs
MPDs Associate Director, Stanford Myelodysplastic Syndromes Center Director, Hematology Division Tissue Bank Director, Med 8, Inpatient Hematology Service
Peter L. Greenberg, MD
Professor, Emeritus (Active)
As Director of the Stanford MDS Center, Dr Greenberg has an active clinical practice focusing on the evaluation and treatment of myelodysplastic syndromes (MDS) and clonal myeloid disorders. His clinical research involves design and coordination of clinical trials using experimental drugs with biologic focus for both lower and higher risk MDS patients not responding to standard therapies. He is Coordinator of the International Working Group for Prognosis in MDS (IWG-PM) which generated the revised MDS classification system (the IPSS-R) and is now evaluating the impact of molecular mutations on this risk-based prognostic system. He is Chair of the NCCN Practice Guidelines Panel for MDS.
David Iberri, MD
Clinical Assistant Professor
Caring for patients with multiple myeloma, Waldenström macroglobulinemia, and related plasma-cell and lymphoid disorders.
Using novel biomarkers to personalize therapy and predict treatment response
Participating in clinical trials to advance the care of patients with a variety of hematologic malignancies including MDS, AML, and CLL.
Calvin J. Kuo, MD, PhD
Maureen Lyles D'Ambrogio Professor
Organoid modeling of cancer
Intestinal stem cell biology
Blood-brain barrier vascular biology
Lawrence L.K. Leung, MD
Maureen Lyles D'Ambrogio Professor
Thrombin-activatable carboxypeptidase B2 in the crosstalk between coagulation, thrombosis, inflammation and innate immunity
Thrombin cleavage of osteopontin in cancer biology
Chemerin and insulin resistance
Epidemiology Center in Research and Information (ERIC) in support of genomics at Palo Alto VA
Michaela Liedtke, MD
Associate Professor
Director, Stanford Adolescent and Young Adult (AYA) Cancer Program
Design of clinical trials using new therapeutic strategies and experimental therapeutics for multiple myeloma, amyloidosis and acute lymphoblastic leukemia. Translational research collaborations to investigate the pathophysiology of amyloidosis. Development of a program addressing the unique needs of adolescents and young adults with cancer.
Sydney X. Lu, MD, PhD
Assistant Professor of Medicine
Sydney's laboratory is broadly interested in studying RNA processing and splicing in the contexts of:
1) normal and pathologic immunity and immunotherapy
2) cancer biology
3) normal and malignant hematopoiesis
Ravi Majeti, MD, PhD
RZ Cao Professor of Medicine
Molecular characterization of human acute myeloid leukemia stem cells and their pathogenesis using bioinformatics, genomics, microfluidics, flow cytometry, and xenotransplantation assays in mice Development of novel therapeutic monoclonal antibodies directed against human acute myeloid leukemia stem cell surface antigens Investigation of normal human hematopoiesis and hematopoietic stem cells using similar techniques.
Gabriel Mannis, MD
Assistant Professor
My research focuses on the development of novel therapies for acute leukemia, with a particular interest in immunotherapy, targeted agents, and predictive biomarkers as a means to improve outcomes and quality of life for patients with hematologic malignancies.
Beth A. Martin, MD
Clinical Assistant Professor
Clinical interests include the histiocytoses including HLH/MAS, autoimmune hematology including T-LGL, AIHA, and Castleman. Educational interests include physical diagnosis, clinical decision-making and communication under desperate circumstances, and chemotherapy. My research focuses on HLH.
Bruno Medeiros, MD
Affiliated Professor
My research interests focus on the experimental therapeutics of Acute Myeloid Leukemia (AML) with the ultimate goal of improving our understanding of the genomic abnormalities responsible for leukemogenesis and how these abnormalities can be exploited therapeutically. It also includes the development and incorporation of novel agents into the treatment regimens for young and older patients with AML and those with acute leukemia secondary to antecedent hematologic disorders.
Beverly S. Mitchell, MD
George E. Becker Professor
Role of nucleotides in regulating nucleolar organization, function and cell proliferation
Novel therapies for acute leukemia with correlative studies
Function of a novel DNA repair protein with ubiquitin ligase activity
Elizabeth A. Price, MD, MPH
Assistant Professor
Clinical and laboratory characterization of unexplained anemia of aging Development of clinical protocol evaluating hematologic and functional response to interventions in unexplained anemia of aging
Tait Shanafelt, MD
Jeanie and Stew Ritchie Professor
Determining why people develop CLL and, its precursor condition, monoclonal B-cell lymphocytosis (MBL).
Identifying molecular characteristics and prognostic tools that predict which CLL patients will experience a more aggressive disease course.
Identification and testing of new compounds for treating CLL.
William Shomali, MD
Clinical Assistant Professor
Dr. William Shomali is a Clinical Assistant Professor in Hematology and his goal is to study novel targeted therapies in patients with blood cancers, with a focus on myeloproliferative neoplasms and myelodysplastic syndromes.
James L. Zehnder, MD
Professor
Clinical and laboratory investigation of thrombosis and bleeding disorders Molecular diagnostic testing for inherited thrombophilia and hematololymphoid malignancy
Tian Zhang, MD, PhD
Assistant Professor
Tian Yi Zhang is an Assistant Professor of Medicine in Hematology and a member of Stanford Cancer Institute. She earned her MD and PhD from University of Utah. Dr. Zhang completed her Hematology and Oncology Fellowship at Stanford and is a board-certified hematologist. While at Stanford, she completed post-doctoral training in the laboratory of Ravi Majeti, where she investigated why patients with acute myeloid leukemia (AML) develop bone marrow failure. Dr. Zhang is the recipient of the ASH RTAF award, the A.P. Giannini Fellowship award, SCI fellowship award, and the NIH T32 Hematology Training grant. She was recently awarded the American Cancer Society-Stanford Cancer Institute Pilot Grant to study immune repertoire perturbations in IDH mutated AML. Dr. Zhang’s current research on AML induced bone marrow failure is funded by the National Cancer Institute (NCI) Career Development Award (K08). Her clinical focus includes the comprehensive care of patients with AML and other myeloid malignancies. She hopes to use the cutting edge science uniquely available at Stanford to develop a robust translational medicine program in the Division of Hematology.